Research programme: GPCR-uPAR - Science Park Raf/Heidelberg Pharma AG

Drug Profile

Research programme: GPCR-uPAR - Science Park Raf/Heidelberg Pharma AG

Alternative Names: Research programme: anticancer therapeutics - Science Park Raf/Heidelberg Pharma; Signal transduction pathway inhibitors - Science Park Raf/Heidelberg Pharma

Latest Information Update: 20 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Science Park Raf
  • Developer Science Park Raf; Wilex
  • Class Antibodies
  • Mechanism of Action G protein-coupled receptor antagonists; Signal transduction pathway inhibitors; Urokinase-type plasminogen activator inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 22 Feb 2005 Preclinical trials in Cancer in Germany (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top